In 2024, Cspc Pharmaceutical Group completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).
However, Cspc Pharmaceutical Group has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021-2019 |
|---|---|---|---|---|
Total Scope 1 | 474,567.04a | 663,224a | 564,429a | |
Total Scope 2 | ||||
Unspecified Calculation Method | 493,310a | 418,037a | 572,613a | |
Total Scope 3 | N/A | N/A | N/A | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 119.3908a | 149.8733a | 127.0384a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2024, the total operational greenhouse gas (GHG) emissions of Cspc Pharmaceutical Group amounted to 967,877.04 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2023, the total operational greenhouse gas (GHG) emissions of Cspc Pharmaceutical Group decreased by 10.49%, showing that the company has made progress in taking action to reduce the climate impact of its operations.a
In 2024, the total Scope 1 emissions of Cspc Pharmaceutical Group were 474,567.04 metric tons of CO₂ equivalent (tCO₂e).a
Since 2020, Cspc Pharmaceutical Group's Scope 1 emissions have increased by 36.07%, reflecting a rising long-term trend in Scope 1 emissions over time.ab
Compared to the previous year (2023), Cspc Pharmaceutical Group's Scope 1 emissions decreased by 28.45%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.a
In 2024, Cspc Pharmaceutical Group reported Scope 2 greenhouse gas (GHG) emissions of 493,310 tCO₂e without specifying the calculation method.a
Since 2020, Cspc Pharmaceutical Group's Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method) have decreased by 29.41%, reflecting a declining long-term trend in Scope 2 emissions over time.ab
Compared to the previous year (2023), Cspc Pharmaceutical Group's Scope 2 emissions (Unspecified Calculation Method) rose by 18.01% in 2024, suggesting that the company faced challenges in reducing emissions from purchased electricity and energya
In 2024, Cspc Pharmaceutical Group reported its Scope 2 emissions using an unspecified methodology.a
In 2024, Cspc Pharmaceutical Group reported Scope 1 greenhouse gas (GHG) emissions of 474,567.04 tCO₂e and total revenues of USD 3,975 millions. This translates into an emissions intensity of 119.39 tCO₂e per millions USD.a
In 2024, Cspc Pharmaceutical Group reported a Scope 1 emissions intensity of 119.39 tCO₂e per millions USD. Compared to the peer group median of 5.15, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a
In 2024, Cspc Pharmaceutical Group ranked 25 out of 25 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
This places Cspc Pharmaceutical Group among the least efficient performers, with one of the highest emissions intensities in its sector.a